JP2011500731A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500731A5 JP2011500731A5 JP2010530233A JP2010530233A JP2011500731A5 JP 2011500731 A5 JP2011500731 A5 JP 2011500731A5 JP 2010530233 A JP2010530233 A JP 2010530233A JP 2010530233 A JP2010530233 A JP 2010530233A JP 2011500731 A5 JP2011500731 A5 JP 2011500731A5
- Authority
- JP
- Japan
- Prior art keywords
- active agent
- formulation
- dry powder
- formulation according
- metered dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013543 active substance Substances 0.000 claims 11
- 238000009472 formulation Methods 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 229940112141 dry powder inhaler Drugs 0.000 claims 4
- 229940071648 metered dose inhaler Drugs 0.000 claims 4
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims 3
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 229960002744 mometasone furoate Drugs 0.000 claims 3
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical group O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 3
- 229960005127 montelukast Drugs 0.000 claims 3
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical group C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims 2
- 229960003728 ciclesonide Drugs 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940125369 inhaled corticosteroids Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32707P | 2007-10-25 | 2007-10-25 | |
| PCT/CA2008/001874 WO2009052624A1 (en) | 2007-10-25 | 2008-10-23 | Combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011500731A JP2011500731A (ja) | 2011-01-06 |
| JP2011500731A5 true JP2011500731A5 (enExample) | 2011-12-08 |
Family
ID=40579006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530233A Pending JP2011500731A (ja) | 2007-10-25 | 2008-10-23 | 併用療法 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20100210611A1 (enExample) |
| EP (1) | EP2211863A4 (enExample) |
| JP (1) | JP2011500731A (enExample) |
| KR (1) | KR20100072295A (enExample) |
| CN (1) | CN101909626A (enExample) |
| AU (1) | AU2008316283A1 (enExample) |
| CA (1) | CA2701956A1 (enExample) |
| CO (1) | CO6270213A2 (enExample) |
| CR (1) | CR11439A (enExample) |
| DO (1) | DOP2010000122A (enExample) |
| GT (1) | GT201000107A (enExample) |
| IL (1) | IL205182A0 (enExample) |
| MA (1) | MA33705B1 (enExample) |
| MX (1) | MX2010004529A (enExample) |
| NI (1) | NI201000069A (enExample) |
| NZ (1) | NZ584876A (enExample) |
| RU (1) | RU2470639C2 (enExample) |
| WO (1) | WO2009052624A1 (enExample) |
| ZA (1) | ZA201002562B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012168907A1 (en) | 2011-06-10 | 2012-12-13 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising revamilast and montelukast or zafirlukast |
| WO2014012954A1 (en) | 2012-07-18 | 2014-01-23 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma |
| JP2017503814A (ja) | 2014-01-22 | 2017-02-02 | タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ | 部分的コントロール状態の重症喘息またはコントロール不良状態の重症喘息のｐｄｅ４インヒビターを用いた（およびロイコトリエン調節薬と組み合わせて用いた）治療 |
| CN108267531B (zh) * | 2016-12-31 | 2022-01-11 | 天津金耀集团有限公司 | 一种环索奈德有关物质hplc测定方法 |
| IT201900014178A1 (it) | 2019-08-06 | 2021-02-06 | Genetic S P A | Esteri del montelukast e loro formulazioni farmaceutiche |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837699A (en) * | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| US20040214805A1 (en) * | 1999-11-02 | 2004-10-28 | Smithkline Beecham Corporation | Method and compositions for treating pulmonary diseases |
| CA2427814C (en) * | 2000-11-07 | 2009-06-02 | Merck & Co., Inc. | A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders |
| JO2311B1 (en) * | 2001-08-29 | 2005-09-12 | ميرك فروست كندا ليمتد | Alkyl inhibitors Ariel phosphodiesterase-4 |
| WO2003024488A2 (en) * | 2001-09-19 | 2003-03-27 | Altana Pharma Ag | Combination of a pde inhibitor and a leukotriene receptor antagonist |
| DE10237739A1 (de) * | 2002-08-17 | 2004-02-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika |
| US7550133B2 (en) * | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
| PL1670482T5 (pl) * | 2003-09-16 | 2022-10-03 | Covis Pharma Gmbh | Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego |
| IL174758A (en) * | 2003-10-10 | 2012-09-24 | Synthon Bv | Crystalline form of montelukast, pharmaceutical composition comprising it, process for the preparation thereof and uses thereof as a medicament |
| HRP20120286T1 (hr) * | 2004-02-06 | 2012-04-30 | Meda Pharma Gmbh & Co. Kg | Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti |
| EP1616567A1 (en) * | 2004-07-16 | 2006-01-18 | Boehringer Ingelheim Pharma GmbH & Co.KG | Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts |
| US20070065374A1 (en) * | 2005-03-16 | 2007-03-22 | Elan Pharma International Limited | Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations |
| CN101128196B (zh) * | 2005-03-16 | 2013-01-02 | Meda制药有限及两合公司 | 用于治疗呼吸系统疾病的抗胆碱能药和白三烯受体拮抗剂的组合 |
| CA2623882A1 (en) * | 2005-09-28 | 2007-04-05 | Merck Frosst Canada Ltd. | Aerosol powder formulation comprising sieved lactose |
-
2008
- 2008-10-23 JP JP2010530233A patent/JP2011500731A/ja active Pending
- 2008-10-23 CN CN2008801225895A patent/CN101909626A/zh active Pending
- 2008-10-23 NZ NZ584876A patent/NZ584876A/en not_active IP Right Cessation
- 2008-10-23 KR KR1020107009041A patent/KR20100072295A/ko not_active Withdrawn
- 2008-10-23 RU RU2010120806/15A patent/RU2470639C2/ru not_active IP Right Cessation
- 2008-10-23 CA CA2701956A patent/CA2701956A1/en not_active Abandoned
- 2008-10-23 WO PCT/CA2008/001874 patent/WO2009052624A1/en not_active Ceased
- 2008-10-23 US US12/738,946 patent/US20100210611A1/en not_active Abandoned
- 2008-10-23 EP EP08842623A patent/EP2211863A4/en not_active Withdrawn
- 2008-10-23 MX MX2010004529A patent/MX2010004529A/es not_active Application Discontinuation
- 2008-10-23 AU AU2008316283A patent/AU2008316283A1/en not_active Abandoned
-
2010
- 2010-04-13 ZA ZA2010/02562A patent/ZA201002562B/en unknown
- 2010-04-18 IL IL205182A patent/IL205182A0/en unknown
- 2010-04-19 GT GT201000107A patent/GT201000107A/es unknown
- 2010-04-22 CO CO10047531A patent/CO6270213A2/es not_active Application Discontinuation
- 2010-04-22 NI NI201000069A patent/NI201000069A/es unknown
- 2010-04-23 DO DO2010000122A patent/DOP2010000122A/es unknown
- 2010-05-18 CR CR11439A patent/CR11439A/es not_active Application Discontinuation
- 2010-05-20 MA MA32860A patent/MA33705B1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019100425A (ru) | Новая доза и препаративная форма | |
| JP2011520911A5 (enExample) | ||
| JP2010132695A5 (enExample) | ||
| RU2013142268A (ru) | Фармацевтическая композиция | |
| HRP20130835T1 (hr) | Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru | |
| JP2016040316A5 (enExample) | ||
| NZ585856A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| JP2018199684A5 (enExample) | ||
| JP2007106777A5 (enExample) | ||
| NZ606548A (en) | Dry powder formulation comprising a phosphodiesterase inhibitor | |
| JP2013531056A5 (enExample) | ||
| JP2019517597A5 (enExample) | ||
| JP2004514739A5 (enExample) | ||
| JP2015519356A5 (enExample) | ||
| JP2014510064A5 (enExample) | ||
| HK1203149A1 (en) | Novel dosage form and formulation of abediterol | |
| JP2007520506A5 (enExample) | ||
| JP2013542940A5 (enExample) | ||
| WO2014016548A3 (en) | Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient | |
| JP2016510012A5 (enExample) | ||
| JP2011500731A5 (enExample) | ||
| RU2008124825A (ru) | Органические соединения, включающие соль гликопиррония | |
| AU2015261104A1 (en) | Combinations of formoterol and budesonide for the treatment of COPD | |
| RU2010120806A (ru) | Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид | |
| JP2014520874A5 (enExample) |